Argenica Therapeutics Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Liz Dallimore

Algemeen directeur

AU$424.2k

Totale compensatie

Percentage CEO-salaris	67.8%
Dienstverband CEO	2.6yrs
Eigendom CEO	1.3%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.3yrs

Recente managementupdates

Recent updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Sep 23

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Apr 29

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Dec 30

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Sep 16

Analyse CEO-vergoeding

Hoe is Liz Dallimore's beloning veranderd ten opzichte van Argenica Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$424k	AU$288k	-AU$5m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$5m
Sep 30 2023	n/a	n/a	-AU$5m
Jun 30 2023	AU$675k	AU$250k	-AU$5m
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$4m
Sep 30 2022	n/a	n/a	-AU$4m
Jun 30 2022	AU$337k	AU$228k	-AU$4m
Mar 31 2022	n/a	n/a	-AU$3m
Dec 31 2021	n/a	n/a	-AU$3m
Sep 30 2021	n/a	n/a	-AU$2m
Jun 30 2021	AU$145k	AU$31k	-AU$1m

Compensatie versus markt: De totale vergoeding ($USD 278.10K ) Liz } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 299.27K ).

Compensatie versus inkomsten: De vergoeding van Liz is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Liz Dallimore

2.6yrs

Tenure

AU$424,246

Compensatie

Dr. Liz Dallimore (B. Sc. (Hons), MBA, PhD, GAICD) serves as Chief Executive Officer of Argenica Therapeutics Limited ands serves as its Managing Director and Director since April 4, 2022. She is a researc...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Liz Dallimore	CEO, MD & Director	2.6yrs	AU$424.25k	1.28% A$ 1.3m
Dianne Angus	Independent Non-Executive Chairman	less than a year	AU$102.58k	geen gegevens
Geoffrey Donnan	Member of Clinical Advisory Committee	no data	geen gegevens	geen gegevens
Terence Budge	Independent Non-Executive Director	3.8yrs	AU$44.40k	0.63% A$ 620.4k
Elizabeth McCall	Independent Non-Executive Director	3.9yrs	AU$44.40k	0.35% A$ 341.2k
Robert Black	Independent Non-Executive Director	less than a year	geen gegevens	0.020% A$ 19.3k
Paul Bailey	Member of Clinical Advisory Committee	no data	geen gegevens	geen gegevens
Tim Phillips	Member of Clinical Advisory Committee	no data	geen gegevens	geen gegevens
David Blacker	Chairman of Clinical Advisory Committee	no data	geen gegevens	geen gegevens
Jeffery Saver	Member of Clinical Advisory Committee	2.3yrs	geen gegevens	geen gegevens
Mark Etherton	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van AGN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.

Argenica Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Ms. Liddy Mccall Intends Not Stand for Re-Election as Non-Executive Director of Argenica Therapeutics Limited

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

Less than half of directors are independent

Recent updates

Ms. Liddy Mccall Intends Not Stand for Re-Election as Non-Executive Director of Argenica Therapeutics Limited

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics Limited Announces Preclinical Data Shows ARG-007 Inhibits A Cause of Alzheimers

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Approves Commencement of Fourth and Final Cohort Dosing

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Announces That the First Subjects in the Third Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Dosed

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee (SRC) to Progress to the Third Escalated Dose Cohort

Less than half of directors are independent

Argenica Therapeutics Limited Announces Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Second Escalated Dose Cohort

Argenica Therapeutics Limited Announces Healthy Participants in the First Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Successfully Dosed, Indicating Good Safety and Tolerability of ARG-007 in These Participants

Argenica Therapeutics Limited Announces First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

Argenica Therapeutics Limited Announces Further Positive Preclinical Results for ARG-007 in Hypoxic-Ischaemic Encephalopathy

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Argenica Therapeutics Limited Announces Phase 1 Clinical Trial Summary

Argenica Therapeutics Limited Receives Ethics Approval to Commence Phase 1 Trial

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Argenica Therapeutics Limited Submits Application to Seek Approval to Commence Phase 1 Healthy Participant Study of ARG-007

Argenica Therapeutics Limited Appoints Dr. Jeffery Saver to Clinical Advisory Committee

Argenica Therapeutics Limited Announces Completion of the Final Pharmacokinetic (PK) Study of ARG-007 Required for the Phase 1 Clinical Trial

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Argenica Therapeutics Limited Announces Results of In-Life Rodent and Non-Human Primate Toxicology Studies Which Have Established the Maximum Tolerated Dose (MTD) of ARG-007

Less than half of directors are independent

Less than half of directors are independent

Argenica Therapeutics Limited Announces Management Changes

Argenica Therapeutics Limited Announces Positive Preclincal Data on Efficacy of ARG-007

Argenica Therapeutics Limited Announces Successful Completion of Final GLP Genotoxicity Studies

Argenica Therapeutics Announces Completion of Preliminary Pre-Clinical Tox Studies

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Provides Additional Information of Study Shows ARG-007 Does Not Degrade

Argenica Therapeutics Limited Provides Positive Preliminary for ARG-007

Argenica Therapeutics Limited Completes Pilot Pre-Clinical Pharmacokinetics Study

Argenica Therapeutics Limited has completed an IPO in the amount of AUD 7 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur